SCHEMBL2840775

SCHEMBL2840775

O=C(O)C(O)C(=O)NCCc1ccc(-c2ccccc2)nc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
HIF1A Q16665 3/20 0.42
LDHA P00338 1/20 0.42
WNT3A P56704 1/20 0.42
HDAC1 Q13547 1/20 0.42
MMP8 P22894 1/20 0.42
CYP11B1 P15538 4/20 0.42
CYP11B2 P19099 4/20 0.42
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
ECE1 P42892 1/20 0.41
BAZ2B Q9UIF8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2846480 0.84 HPGDS (0.52) HPGDSNPC1RAB9ASMN1; SMN2TP53
SCHEMBL2409500 0.76 SMN1; SMN2 (0.44) HPGDSNPC1RAB9ASMN1; SMN2TP53
SCHEMBL2840773 0.76 HPGDS (0.45) HPGDSNPC1RAB9ASMN1; SMN2TP53
SCHEMBL2412802 0.76 LMNA (0.53) HPGDSSMN1; SMN2HIF1A
SCHEMBL2414440 0.76 RAB9A (0.44) HPGDSNPC1RAB9ASMN1; SMN2TP53
SCHEMBL17892335 0.76 TPH1 (0.53) HPGDSNPC1RAB9ASMN1; SMN2HDAC1
SCHEMBL17892337 0.76 TPH1 (0.53) HPGDSNPC1RAB9ASMN1; SMN2HDAC1
SCHEMBL17261555 0.75 ALDH1A1 (0.50) NPC1RAB9ASMN1; SMN2
SCHEMBL6027765 0.75 HPGDS (0.44) HPGDSNPC1RAB9ASMN1; SMN2TP53
SCHEMBL17273999 0.75 CKS1B (0.50) HPGDSNPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2251324-A1 HETEROARYL-ALKYLCARBAMATE COMPOUNDS AND THEIR USE AS INHIBITORS OF THE FAAH ENZYME Sanofi-Aventis (FR) 2010-11-17 EP disclosed
US-7645757-B2 Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2010-01-12 US disclosed
EP-1720829-B1 DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-10-14 EP disclosed
US-20070021426-A1 DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021426-A1 DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 HPGDS 241/4885NPC1 992/4885RAB9A 2188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.